CRANDELL KEITH 4

What Happened

• Keith Crandell, a director of Twist Bioscience (TWST), was granted an annual equity award of 5,095 shares on February 5, 2026. The grant price is listed as $0.00 (transaction code A), so the reported acquisition value is $0.
• This is a compensation grant to a non-employee director rather than an open-market purchase or sale, and does not represent an immediate cash investment by the insider.

Key Details

• Transaction date: 2026-02-05; Form 4 filed: 2026-02-09 (timely under SEC rules).
• Shares granted: 5,095; reported acquisition price: $0.00; total reported value: $0.
• Vesting: Footnote indicates 100% of the shares will vest on the earlier of (i) the one‑year anniversary of the grant or (ii) the first annual meeting of stockholders following the grant, provided the director remains a service provider on each vesting date.
• Ownership after transaction: not specified in the provided filing.
• Additional filing detail: Reporting person is co-trustee with spouse; he is sole beneficiary of the Keith L. Crandell Trust (per footnote).

Context

• Director equity awards are common as compensation and align directors’ interests with shareholders; they are routine and don’t necessarily signal the director buying or selling based on a view of the stock.
• Because this was a grant (not a purchase or sale), there was no immediate cash outlay or proceeds to report.